Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were
demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU,
Canada and Australia. In this study, the long-term safety and efficacy after administrations
of sitaxentan sodium at a dose of 100 mg alone or in combination with another medication will
be investigated in Japanese PAH patients.